Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Clinical trial NCT04414969 · UNKNOWN

Trial details

NCT number: NCT04414969
Sponsor: Hunan Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Immune Checkpoint Inhibitor Chemotherapy Effect Epigenetic Disorder NK/T-cell Lymphoma of Nasal Cavity

Start date: 2020-06-26
Primary completion: 2022-07-01
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.